Forty-two patients with refractory acute myeloid leukemia received intravenous (IV) (NCT01385423) or subcutaneous (SC) (NCT02395822) recombinant human IL-15 (rhIL-15) after lymphodepleting chemotherapy and haploidentical NK cell infusions (75). This evidence concerns the gene IL15 and acute myeloid leukemia.